CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 30 enrolled
Drug / intervention
evolocumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03403374
NCT03403374Phase 4Completed
CompareCT.gov

A Multicenter, Open-label, Single-arm, Study to Evaluate Safety and Tolerability of Repatha in Patients With Homozygous Familial Hypercholesterolemia (HoFH) in India

Amgen·interventional·Posted Jan 18, 2018·Updated May 29, 2024

In Brief

A Phase 4 clinical trial evaluating evolocumab for Homozygous Familial Hypercholesterolemia HoFH. Completed, enrolled 30 participants across 12 sites.

Detailed Summary

To describe the safety and tolerability of evolocumab in participants with homozygous familial hypercholesterolemia (HoFH) in India. All participants will receive evolocumab over an 8-week period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHomozygous Familial Hypercholesterolemia HoFH
CountriesIndia
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedJan 18, 2018
Enrollment StartAug 4, 2018
Primary CompletionNov 27, 2019
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 8.5 years ago

Interventions

evolocumabdrug

Administered by SC injection via autoinjector (AI)/pen